Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference

Findings Provide Further Support for the Rationale Behind Bionor Pharma`s Second HIV Vaccine, Vacc-C5 (Oslo, 5 April 2013)  Bionor Pharma ASA (OSE: BIONOR) today announced that their scientific work entitled “The C5 region of HIV-1 gp120 shares homology with the shared epitope of HLA-DRß1 and activates immune responses. Anti-C5 antibodies correlate with protection from HIV-1 disease …

Read more

Patent Application Submitted With Bionor Pharma`s HIV-Vaccines for Use in Combination Therapy

Oslo 26.02.2013 – The combination with complementary formulations aims to optimize future HIV treatments Bionor Pharma ASA (OSE: BIONOR) today announced that a new patent application relating to the Company`s HIV-vaccines Vacc-4x and Vacc-C5 has been submitted. The patent application contains claims covering various combinations of our vaccines with other agents such as immune modulators …

Read more